Cannabinoid-1 receptor inhibition prevents the reduction of 24-hour energy expenditure with weight loss

Metabolism: Clinical and Experimental

Volumn 61, Issue 4, 2012, Pages 546-553

  Strack, Alison M ^a   Nicolich, Susan ^a   Faidley, Terry ^b   Achanfuo Yeboah, Joana ^a   Cunningham, Paul K ^a   Hora Jr , Donald ^a   Thompson, Donald ^a   Hickey, Gerry ^a   Johnson Levonas, Amy O ^a   Fong, Tung M ^c   Heymsfield, Steven B ^d  

^a MERCK RESEARCH LABORATORIES   (United States)

^b Faidley Nutrition   (United States)

^c FOREST RESEARCH INSTITUTE   (United States)

^d PENNINGTON BIOMEDICAL RESEARCH CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 (2,4 DICHLOROPHENYL) 5 (4 IODOPHENYL) 4 METHYL N (1 PIPERIDYL) 1H PYRAZOLE 3 CARBOXAMIDE; CANNABINOID 1 RECEPTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BODY MASS; BODY WEIGHT; CONTROLLED STUDY; DIET RESTRICTION; DUAL ENERGY X RAY ABSORPTIOMETRY; ENERGY EXPENDITURE; EXPERIMENTAL DOG; FEMALE; FOOD INTAKE; LEAN BODY WEIGHT; MAINTENANCE THERAPY; NONHUMAN; OBESITY; PRIORITY JOURNAL; WEIGHT REDUCTION;

ABSORPTIOMETRY, PHOTON; ANIMALS; DISEASE MODELS, ANIMAL; DOGS; EATING; ENERGY METABOLISM; FEMALE; GLUCOSE TOLERANCE TEST; OBESITY; PIPERIDINES; PYRAZOLES; RANDOM ALLOCATION; RECEPTOR, CANNABINOID, CB1; WEIGHT LOSS;

EID: 84858440908     PISSN: 00260495     EISSN: 15328600     Source Type: Journal    
DOI: 10.1016/j.metabol.2011.09.002     Document Type: Article

References (36)

1. D. Osei-Hyiaman, J. Harvey-White, and S. Batkai The role of the endocannabinoid system in the control of energy homeostasis Int J Obes (Lond) 30 Suppl 1 2006 S33 S38
2. A.C. Howlett, F. Barth, and T.I. Bonner International Union of Pharmacology. XXVII. Classification of cannabinoid receptors Pharmacol Rev 54 2002 161 202 (Pubitemid 34575709)
3. I. Matias, M.P. Gonthier, and P. Orlando Regulation, function, and dysregulation of endocannabinoids in models of adipose and beta-pancreatic cells and in obesity and hyperglycemia J Clin Endocrinol Metab 91 2006 3171 3180 (Pubitemid 44271774)
4. Marzo Di V, S.K. Goparaju, and L. Wang Leptin-regulated endocannabinoids are involved in maintaining food intake Nature 410 2001 822 825 (Pubitemid 32303781)
5. A.N. Verty, J.R. McFarlane, and I.S. McGregor Evidence for an interaction between CB1 cannabinoid and oxytocin receptors in food and water intake Neuropharmacology 47 2004 593 603 (Pubitemid 39221781)
6. K.M. Gamber, H. Macarthur, and T.C. Westfall Cannabinoids augment the release of neuropeptide Y in the rat hypothalamus Neuropharmacology 49 2005 646 652 (Pubitemid 41208286)
7. S.A. Tucci, E.K. Rogers, and M. Korbonits The cannabinoid CB1 receptor antagonist SR141716 blocks the orexigenic effects of intrahypothalamic ghrelin Br J Pharmacol 143 2004 520 523 (Pubitemid 39524268)
8. T.C. Ravinet, C. Delgorge, and C. Menet CB1 cannabinoid receptor knockout in mice leads to leanness, resistance to diet-induced obesity and enhanced leptin sensitivity Int J Obes Relat Metab Disord 28 2004 640 648 (Pubitemid 38491158)
9. S. Hao, Y. Avraham, and R. Mechoulam Low dose anandamide affects food intake, cognitive function, neurotransmitter and corticosterone levels in diet-restricted mice Eur J Pharmacol 392 2000 147 156 (Pubitemid 30184903)
10. N. Jamshidi, and D.A. Taylor Anandamide administration into the ventromedial hypothalamus stimulates appetite in rats Br J Pharmacol 134 2001 1151 1154 (Pubitemid 33097243)
11. T.C. Kirkham, C.M. Williams, and F. Fezza Endocannabinoid levels in rat limbic forebrain and hypothalamus in relation to fasting, feeding and satiation: stimulation of eating by 2-arachidonoyl glycerol Br J Pharmacol 136 2002 550 557 (Pubitemid 34717699)
12. T.M. Fong, X.M. Guan, and D.J. Marsh Antiobesity efficacy of a novel cannabinoid-1 receptor inverse agonist, N-[(1S,2S)-3-(4-chlorophenyl)-2-(3- cyanophenyl)-1-methylpropyl]-2-methyl-2 -[[5-(trifluoromethyl)pyridin-2-yl]oxy] propanamide (MK-0364), in rodents J Pharmacol Exp Ther 321 2007 1013 1022 (Pubitemid 46762708)
13. A.J. Tallett, J.E. Blundell, and R.J. Rodgers Effects of acute low-dose combined treatment with rimonabant and sibutramine on appetite and weight gain in rats Pharmacol Biochem Behav 2009
14. A.W. Herling, S. Kilp, and R. Elvert Increased energy expenditure contributes more to the body weight-reducing effect of rimonabant than reduced food intake in candy-fed Wistar rats Endocrinology 149 2008 2557 2566 (Pubitemid 351574492)
15. C. Addy, H. Wright, and K. Van Laere The acyclic CB1R inverse agonist taranabant mediates weight loss by increasing energy expenditure and decreasing caloric intake Cell Metab 7 2008 68 78
16. A.W. Herling, M. Gossel, and G. Haschke CB1 receptor antagonist AVE1625 affects primarily metabolic parameters independently of reduced food intake in Wistar rats Am J Physiol Endocrinol Metab 293 2007 E826 E832
17. I. Kunz, M.K. Meier, and A. Bourson Effects of rimonabant, a cannabinoid CB1 receptor ligand, on energy expenditure in lean rats Int J Obes (Lond) 32 2008 863 870 (Pubitemid 351670628)
18. Y.L. Liu, I.P. Connoley, and C.A. Wilson Effects of the cannabinoid CB1 receptor antagonist SR141716 on oxygen consumption and soleus muscle glucose uptake in Lep(ob)/Lep(ob) mice Int J Obes (Lond) 29 2005 183 187 (Pubitemid 40188413)
19. A.N.A. Verty, A.M. Allen, and B.J. Oldfield The effects of rimonabant on brown adipose tissue in rat: implications for energy expenditure Obesity 17 2009 254 261
20. L.J. Aronne, S. Tonstad, and M. Moreno A clinical trial assessing the efficacy and safety of taranabant, a CB1R inverse agonist, in obese and overweight patients: a high-dose study Int J Obes (Lond) 34 2010 919 935
21. F.X. Pi-Sunyer, L.J. Aronne, and H.M. Heshmati Effect of rimonabant, a cannabinoid-1 receptor blocker, on weight and cardiometabolic risk factors in overweight or obese patients: RIO-North America: a randomized controlled trial JAMA 295 2006 761 775 (Pubitemid 43244304)
22. S.L. Lindstedt, and P.J. Schaeffer Use of allometry in predicting anatomical and physiological parameters of mammals Lab Anim 36 2002 1 19 (Pubitemid 34073118)
23. T.M. Fong, L.P. Shearman, and D.S. Stribling Pharmacological efficacy and safety profile of taranabant in preclinical species Drug Dev Res 70 2009 349 362
24. P.J. McLaughlin, K. Winston, and L. Swezey The cannabinoid CB1 antagonists SR 141716A and AM 251 suppress food intake and food-reinforced behavior in a variety of tasks in rats Behav Pharmacol 14 2003 583 588
25. L.R. McMahon, and W. Koek Differences in the relative potency of SR 141716A and AM 251 as antagonists of various in vivo effects of cannabinoid agonists in C57BL/6J mice Eur J Pharmacol 569 2007 70 76 (Pubitemid 47175872)
26. J.R. Speakman, and E. Krol Comparison of different approaches for the calculation of energy expenditure using doubly labeled water in a small mammal Physiol Biochem Zool 78 2005 650 667 (Pubitemid 40870449)
27. A.J. German, S.L. Holden, T. Bissot, R.M. Hackett, and V. Biourge Dietary energy restriction and successful weight loss in obese client-owned dogs J Vet Intern Med 21 2010 1174 1180 (Pubitemid 350303618)
28. E. Raffan, S.L. Holden, and F. Cullingham Standardized positioning is essential for precise determination of body composition using dual-energy x-ray absorptiometry in dogs J Nutr 136 2006 1976S 1978S (Pubitemid 43973610)
29. K. Goele, A. Bosy-Westphal, and B. Rumcker Influence of changes in body composition and adaptive thermogenesis on the difference between measured and predicted weight loss in obese women Obes Facts 2 2009 105 109
30. D.P. Laflamme Development and validation of a body condition score system for dogs Canine Pract 22 1997 10 15
31. E.T. Tzavara, K.W. Perry, and D.E. Rodriguez The cannabinoid CB(1) receptor antagonist SR141716A increases norepinephrine outflow in the rat anterior hypothalamus Eur J Pharmacol 426 2001 R3 R4
32. J.M. Richey, O.O. Woolcott, and D. Stefanovski Rimonabant prevents additional accumulation of visceral and subcutaneous fat during high-fat feeding in dogs Am J Physiol Endocrinol Metab 296 2009 E1311 E1318
33. N. Sasaki, E. Uchida, and M. Niiyama Anti-obesity effects of selective agonists to the beta 3-adrenergic receptor in dogs. II. Recruitment of thermogenic brown adipocytes and reduction of adiposity after chronic treatment with a beta 3-adrenergic agonist J Vet Med Sci 60 1998 465 469 (Pubitemid 128531781)
34. A.M. Cypess, S. Lehman, and G. Williams Identification and importance of brown adipose tissue in adult humans N Engl J Med 360 2009 1509 1517
35. M. Simeckova, L. Jansky, and I. Lesna I Role of beta adrenoceptors in metabolic and cardiovascular responses of cold exposed humans J Therm Biol 25 2000 437 442
36. R. Christensen, P.K. Kristensen, and E.M. Bartels Efficacy and safety of the weight-loss drug rimonabant: a meta-analysis of randomised trials Lancet 370 2007 1706 1713 (Pubitemid 350100788)